22
Participants
Start Date
October 31, 2002
Primary Completion Date
September 30, 2007
Study Completion Date
September 30, 2007
Somatropin (recombinant human growth hormone)
3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
Gladstone Institute of Virology and Immunology, San Francisco
Collaborators (1)
The J. David Gladstone Institutes
OTHER
University of California, San Francisco
OTHER
National Center for Research Resources (NCRR)
NIH
EMD Serono
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH